As
we navigate the spring of 2026, the familiar hum of the COVID-19 pandemic has
taken on a new, more literal tone. A highly mutated variant, officially
designated as BA.3.2 but colloquially known as "Cicada," is currently
spreading across the United States and dozens of other countries. Much like the
insect that shares its name, this variant was first detected in South Africa in
late 2024 before seemingly going "underground" for months, only to
resurface with a vengeance in Europe and North America. While health officials
emphasize that current infection levels remain relatively low, the sheer
genetic divergence of this strain has put the global scientific community on
high alert.
The
Story of the "Undead" Lineage
To
understand why "Cicada" is causing a stir, one must look at its
family tree. Most variants that have dominated the headlines over the last two
years, such as the JN.1 lineage, follow a predictable evolutionary path.
However, BA.3.2 is different. It traces its ancestry back to BA.3, a branch of
the Omicron family that scientists thought had largely vanished by mid-2022.
This unexpected return has led some researchers to label it an "undead
variant," suggesting it may have evolved secretly within a single chronically
infected individual over several years—a process known as "cryptic
evolution"—before finally re-emerging into the general population.
The
variant was first identified in a nasopharyngeal swab from a five-year-old boy
in South Africa on November 22, 2024. By early 2025, it began appearing in
Mozambique and eventually reached Europe by April of that year. In the United
States, the first documented arrival occurred on June 27, 2025, when the CDC’s
Traveler-Based Genomic Surveillance (TGS) program identified the strain in a
participant arriving at San Francisco International Airport from the
Netherlands.
A
Master of Disguise: 75 Mutations
The
primary reason for concern regarding BA.3.2 is its spike protein, the part of
the virus that acts as a "key" to enter human cells. This variant
carries between 70 and 75 mutations in this protein relative to the JN.1 and
LP.8.1 strains that the current 2025–2026 vaccines were designed to target.
This genetic distance is the largest leap seen since the original emergence of
Omicron.
Biologically,
these mutations translate to a high degree of "immune escape". In
laboratory studies, BA.3.2 has shown an ability to evade the antibodies
produced by both prior infections and current vaccinations more efficiently
than any other currently circulating strain. As Joe Coyle, director of the
Bureau of Infectious Disease Prevention at the Michigan Department of Health
and Human Services, explained, the variant contains changes in the exact areas
where the body normally produces defenses. This suggests that even if you have
stayed up to date with your shots, your immune system might take longer to
recognize and fight off this specific version of the virus.
Mapping
the Spread: Wastewater and Clinical Clues
As
of March 2026, BA.3.2 has been detected in at least 23 to 29 countries. In
Europe, it gained significant traction over the winter, accounting for
approximately 30% to 40% of cases in Denmark, Germany, and the Netherlands.
In
the United States, the variant is currently a "minority strain,"
accounting for less than 1% of analyzed cases nationwide. However, it has been
confirmed in 25 to 29 states and Puerto Rico. Surveillance data has become
harder to collect as clinical testing has dropped significantly since 2023. To
fill the gaps, health officials are relying heavily on wastewater surveillance,
which often detects the virus weeks before patients show up in clinics. For
instance, by mid-February 2026, BA.3.2 had been identified in 132 wastewater
samples across 25 states, but only in five clinical patient samples during that
same period.
In
Maryland, local doctors are already warning of a potential summer surge driven
by the variant's immune-evasive nature. While case counts remain relatively
low—roughly two infections per 100,000 people—experts like Dr. Tyler Evans,
former New York City Chief Medical Officer, note that the "immune escape
piece" is the key factor they are watching. In Nebraska, infectious
disease expert Mark Rupp, MD, notes that the dominant strains are still from
the XFG lineage, but the landscape is shifting as Omicron subvariants continue
to circulate.
Symptoms
and the Human Impact
For
those who do contract the Cicada variant, the experience remains largely
consistent with previous Omicron strains. Common symptoms include a persistent
cough, fatigue, fever, body aches, and congestion. Some patients have also
reported more specific symptoms like night sweats, skin rashes, and rare bouts
of fainting. Notably, the classic loss of taste or smell is becoming
increasingly rare.
The
broader human impact of COVID-19 continues to be felt through Long COVID, which
researchers are now categorizing into specific subtypes. A massive
meta-analysis of 2.4 million participants released in early 2026 found that
Long COVID often involves overlapping symptoms, with fatigue being the most
common, followed by respiratory issues (affecting 47% of sufferers) and
neurologic symptoms like brain fog (31%). Interestingly, demographic factors
seem to shape these experiences: women are more likely to report
neuropsychiatric symptoms, while men more frequently experience respiratory
problems. Racial disparities also persist, with Black and Hispanic populations
showing higher rates of cardiac and respiratory Long COVID symptoms compared to
White individuals.
The
Vaccine Dilemma and Policy Shifts
As
the virus evolves, so too does the political and regulatory landscape. In May
2025, the FDA advised that 2025–2026 vaccines should target the JN.1/LP.8.1
strains. However, by late 2025, significant changes occurred at the Department
of Health and Human Services (HHS). Secretary Robert F. Kennedy Jr. rescinded
the emergency use authorizations for COVID-19 vaccines, transitioning them to
traditional marketing authorizations with narrower approvals.
Currently,
the updated shots from Pfizer and Moderna are officially approved for adults 65
and older and those at high risk due to underlying conditions. While Kennedy
has stated the shots remain available for anyone who chooses them after
consulting a doctor, the practical reality is that restricted FDA approval and
shifts in funding—including the withdrawal of $500 million for mRNA
development—may limit access for younger, healthy populations at local
pharmacies.
Despite
these shifts, medical experts like Brandon Dionne from Northeastern University
and Dr. Mark Rupp emphasize that the current vaccines still provide the best
protection against severe disease, hospitalization, and death, even if they are
less effective at preventing mild infections from BA.3.2.
Looking
Ahead: Caution Without Panic
While
BA.3.2 is "highly divergent," there is currently no evidence that it
causes more severe illness than previous Omicron strains. Two laboratory
studies suggested that BA.3.2 might be harder to enter lung cells than some of
its rivals, which could explain why it hasn't immediately taken over as the
dominant global strain.
For
the average citizen, the advice remains grounded in the basics: stay up to date
on vaccines if you are in a high-risk group, use at-home tests (which remain
effective for detecting this variant), and practice good hygiene. As Dr. Neil
Maniar of Northeastern University puts it, COVID-19 has become a part of our
day-to-day lives, similar to the flu.
The
"Cicada" variant serves as a reminder that the virus is not finished
evolving. Whether it becomes the next major wave or remains a minority strain
depends on a complex battle between the virus's new mutations and our
collective immunity. For now, scientists are watching the wastewater and the
airports, waiting to see if this "undead" lineage will truly take
flight.
Here
are the 21 primary source references cited in the report, numbered vertically
with traceable URL links:
